Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.

Kanbay M, Copur S, Siriopol D, Yildiz AB, Gaipov A, van Raalte DH, Tuttle KR

Diabetes, obesity & metabolism12 Sept 2023Cited by 37 (Europe PMC)

PMID37700437DOI10.1111/dom.15272PepBankPUB-37700437

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanSystematic reviewEfficacy outcome
In randomized trials, tirzepatide 5 mg lowered systolic blood pressure (median -4.20 mmHg).
In plain wordsIn trials, tirzepatide 5 mg lowered systolic blood pressure.
Peptide
Tirzepatide
Outcome
DecreaseSystolic blood pressure, 5 mg
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
5 mgAs given in this study (human).
Measurements
Median change in systolic blood pressure
−4.2 mmHg
5 mg
Source sentences
Summary
Regardless of the dose administered, tirzepatide resulted in significant decreases in systolic blood pressure of median -4.20 (95% confidence interval [CI] -5.17 to -3.23) mmHg for 5 mg, -5.34 (-6.31 to -4.37) mmHg for 10 mg, and -5.77 (-6.73 to -4.81) mmHg for 15 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included.
Summary · context
Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles.
Report a problemFND-3770043701
02HumanSystematic reviewEfficacy outcome
In randomized trials, tirzepatide 10 mg lowered systolic blood pressure (median -5.34 mmHg).
In plain wordsIn trials, tirzepatide 10 mg lowered systolic blood pressure.
Peptide
Tirzepatide
Outcome
DecreaseSystolic blood pressure, 10 mg
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
10 mgAs given in this study (human).
Measurements
Median change in systolic blood pressure
−5.34 mmHg
10 mg
Source sentences
Summary
Regardless of the dose administered, tirzepatide resulted in significant decreases in systolic blood pressure of median -4.20 (95% confidence interval [CI] -5.17 to -3.23) mmHg for 5 mg, -5.34 (-6.31 to -4.37) mmHg for 10 mg, and -5.77 (-6.73 to -4.81) mmHg for 15 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included.
Summary · context
Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles.
Report a problemFND-3770043702
03HumanSystematic reviewEfficacy outcome
In randomized trials, tirzepatide 15 mg lowered systolic blood pressure (median -5.77 mmHg).
In plain wordsIn trials, tirzepatide 15 mg lowered systolic blood pressure.
Peptide
Tirzepatide
Outcome
DecreaseSystolic blood pressure, 15 mg
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
15 mgAs given in this study (human).
Measurements
Median change in systolic blood pressure
−5.77 mmHg
15 mg
Source sentences
Summary
Regardless of the dose administered, tirzepatide resulted in significant decreases in systolic blood pressure of median -4.20 (95% confidence interval [CI] -5.17 to -3.23) mmHg for 5 mg, -5.34 (-6.31 to -4.37) mmHg for 10 mg, and -5.77 (-6.73 to -4.81) mmHg for 15 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included.
Summary · context
Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles.
Report a problemFND-3770043703
04HumanSystematic reviewEfficacy outcome
In randomized trials, tirzepatide 5 mg lowered total cholesterol (median -3.76%).
In plain wordsIn trials, tirzepatide 5 mg lowered total cholesterol.
Peptide
Tirzepatide
Outcome
DecreaseTotal cholesterol, 5 mg
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
5 mgAs given in this study (human).
Measurements
Median change in total cholesterol
−3.76%
5 mg
Source sentences
Summary
At all three once-weekly doses, tirzepatide treatment resulted in significant decreases in total cholesterol levels: median -3.76% (95% CI -5.20% to -2.31%) for 5 mg; -4.63% (-6.07% to -3.19%) for 10 mg; and -5.93% (-7.36% to -4.49%) for 15 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included.
Summary · context
Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles.
Report a problemFND-3770043704
05HumanSystematic reviewEfficacy outcome
In randomized trials, tirzepatide 10 mg lowered total cholesterol (median -4.63%).
In plain wordsIn trials, tirzepatide 10 mg lowered total cholesterol.
Peptide
Tirzepatide
Outcome
DecreaseTotal cholesterol, 10 mg
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
10 mgAs given in this study (human).
Measurements
Median change in total cholesterol
−4.63%
10 mg
Source sentences
Summary
At all three once-weekly doses, tirzepatide treatment resulted in significant decreases in total cholesterol levels: median -3.76% (95% CI -5.20% to -2.31%) for 5 mg; -4.63% (-6.07% to -3.19%) for 10 mg; and -5.93% (-7.36% to -4.49%) for 15 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included.
Summary · context
Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles.
Report a problemFND-3770043705
06HumanSystematic reviewEfficacy outcome
In randomized trials, tirzepatide 15 mg lowered total cholesterol (median -5.93%).
In plain wordsIn trials, tirzepatide 15 mg lowered total cholesterol.
Peptide
Tirzepatide
Outcome
DecreaseTotal cholesterol, 15 mg
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
15 mgAs given in this study (human).
Measurements
Median change in total cholesterol
−5.93%
15 mg
Source sentences
Summary
At all three once-weekly doses, tirzepatide treatment resulted in significant decreases in total cholesterol levels: median -3.76% (95% CI -5.20% to -2.31%) for 5 mg; -4.63% (-6.07% to -3.19%) for 10 mg; and -5.93% (-7.36% to -4.49%) for 15 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included.
Summary · context
Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles.
Report a problemFND-3770043706
07HumanSystematic reviewEfficacy outcome
In randomized trials, tirzepatide treatment increased HDL cholesterol levels.
In plain wordsIn trials, tirzepatide raised HDL (good) cholesterol.
Peptide
Tirzepatide
Outcome
IncreaseHDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Additionally, tirzepatide treatment led to increased high-density lipoprotein (HDL) cholesterol levels
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included.
Summary · context
Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles.
Report a problemFND-3770043707
08HumanSystematic reviewEfficacy outcome
In randomized trials, tirzepatide treatment decreased LDL cholesterol levels.
In plain wordsIn trials, tirzepatide lowered LDL (bad) cholesterol.
Peptide
Tirzepatide
Outcome
DecreaseLDL cholesterol
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Additionally, tirzepatide treatment led to increased high-density lipoprotein (HDL) cholesterol levels and decreased low-density lipoprotein (LDL) cholesterol and triglyceride levels
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included.
Summary · context
Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles.
Report a problemFND-3770043708
09HumanSystematic reviewEfficacy outcome
In randomized trials, tirzepatide treatment decreased triglyceride levels.
In plain wordsIn trials, tirzepatide lowered triglycerides.
Peptide
Tirzepatide
Outcome
DecreaseTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Additionally, tirzepatide treatment led to increased high-density lipoprotein (HDL) cholesterol levels and decreased low-density lipoprotein (LDL) cholesterol and triglyceride levels
2 context sentences(design, population, supporting numbers)
Summary · context
PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating the effects of tirzepatide on either blood pressure or lipid profiles were included.
Summary · context
Seven randomized controlled trials have investigated the effects of tirzepatide on blood pressure and lipid profiles.
Report a problemFND-3770043709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT07573163

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Alaa Sadan = 3427 Jul 2026 to est. 31 Dec 2028

Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status

Trial page ClinicalTrials.govUpdated 30 Jul 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.